Bio
Dr Strohmenger is one of Europe’s most experienced venture capitalists in Life Sciences. Joining Wellington Partners in 1997, he became a Partner in December 2000. His ten years of investment activity involved financing of some of the most successful European biotech companies. In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, today a listed company with a market cap of more than four billion euros. He was also responsible for the investments in Grandis (acquired by Novartis), Noema Life (Borsa Italiana:NOE), Wavelight (Deutsche Boerse:WLT), as well as immatics. Prior to joining Wellington Partners, Dr Strohmenger was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at Ludwig-Maximilians University in Munich. Dr Strohmenger studied medicine and economics and holds a doctorate in medicine as well as a master's degree in economics.
